Koninklijke Philips NV (PHIA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Koninklijke Philips NV (PHIA) has a cash flow conversion efficiency ratio of 0.031x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€327.00 Million) by net assets (€10.58 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Koninklijke Philips NV - Cash Flow Conversion Efficiency Trend (1991–2024)
This chart illustrates how Koninklijke Philips NV's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Koninklijke Philips NV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Koninklijke Philips NV ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DexCom Inc
NASDAQ:DXCM
|
0.107x |
|
ANTA Sports Products Limited
F:AS7
|
0.073x |
|
PulteGroup Inc
NYSE:PHM
|
0.053x |
|
Holcim Ltd.
LSE:0QKY
|
0.085x |
|
Shengyi Technology Co Ltd
SHG:600183
|
0.071x |
|
Cathay Financial Holding Co Ltd Pref A
TW:2882A
|
0.052x |
|
Markel Corporation
NYSE:MKL
|
0.008x |
|
Novonesis (Novozymes) A/S
CO:NSIS-B
|
0.043x |
Annual Cash Flow Conversion Efficiency for Koninklijke Philips NV (1991–2024)
The table below shows the annual cash flow conversion efficiency of Koninklijke Philips NV from 1991 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €12.04 Billion | €1.57 Billion | 0.130x | -26.44% |
| 2023-12-31 | €12.06 Billion | €2.14 Billion | 0.177x | +1459.78% |
| 2022-12-31 | €13.28 Billion | €-173.00 Million | -0.013x | -111.57% |
| 2021-12-31 | €14.47 Billion | €1.63 Billion | 0.113x | -51.77% |
| 2020-12-31 | €11.90 Billion | €2.78 Billion | 0.233x | +45.05% |
| 2019-12-31 | €12.62 Billion | €2.03 Billion | 0.161x | +9.51% |
| 2018-12-31 | €12.12 Billion | €1.78 Billion | 0.147x | -5.55% |
| 2017-12-31 | €12.02 Billion | €1.87 Billion | 0.156x | +10.35% |
| 2016-12-31 | €13.51 Billion | €1.90 Billion | 0.141x | +42.28% |
| 2015-12-31 | €11.78 Billion | €1.17 Billion | 0.099x | -16.61% |
| 2014-12-31 | €10.97 Billion | €1.30 Billion | 0.119x | +17.20% |
| 2013-12-31 | €11.23 Billion | €1.14 Billion | 0.101x | -48.47% |
| 2012-12-31 | €11.17 Billion | €2.20 Billion | 0.197x | +330.57% |
| 2011-12-31 | €12.39 Billion | €566.00 Million | 0.046x | -68.02% |
| 2010-12-31 | €15.09 Billion | €2.16 Billion | 0.143x | +35.40% |
| 2009-12-31 | €14.64 Billion | €1.54 Billion | 0.106x | +10.04% |
| 2008-12-31 | €15.59 Billion | €1.50 Billion | 0.096x | +52.47% |
| 2007-12-31 | €21.76 Billion | €1.37 Billion | 0.063x | +70.31% |
| 2006-12-31 | €23.13 Billion | €853.92 Million | 0.037x | -69.98% |
| 2005-12-31 | €16.98 Billion | €2.09 Billion | 0.123x | -30.95% |
| 2004-12-31 | €15.13 Billion | €2.69 Billion | 0.178x | +15.69% |
| 2003-12-31 | €12.92 Billion | €1.99 Billion | 0.154x | -2.59% |
| 2002-12-31 | €14.11 Billion | €2.23 Billion | 0.158x | +136.30% |
| 2001-12-31 | €18.69 Billion | €1.25 Billion | 0.067x | -50.44% |
| 2000-12-31 | €22.27 Billion | €3.00 Billion | 0.135x | +6.42% |
| 1999-12-31 | €15.13 Billion | €1.92 Billion | 0.127x | -17.93% |
| 1998-12-31 | €14.36 Billion | €2.22 Billion | 0.154x | -56.25% |
| 1997-12-31 | €9.81 Billion | €3.46 Billion | 0.353x | +107.03% |
| 1996-12-31 | €7.14 Billion | €1.22 Billion | 0.171x | -4.18% |
| 1995-12-31 | €6.82 Billion | €1.21 Billion | 0.178x | -48.90% |
| 1994-12-31 | €6.78 Billion | €2.36 Billion | 0.348x | -20.66% |
| 1993-12-31 | €6.03 Billion | €2.65 Billion | 0.439x | +9.69% |
| 1992-12-31 | €4.13 Billion | €1.65 Billion | 0.400x | +55.04% |
| 1991-12-31 | €5.79 Billion | €1.49 Billion | 0.258x | -- |
About Koninklijke Philips NV
Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. It provides diagnostic imaging solutions, includes magnetic resonance imaging; X-ray systems; and computed tomography (CT) systems and software comprising detector-based spectral… Read more